402 related articles for article (PubMed ID: 17584015)
1. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions.
Kalgutkar AS; Obach RS; Maurer TS
Curr Drug Metab; 2007 Jun; 8(5):407-47. PubMed ID: 17584015
[TBL] [Abstract][Full Text] [Related]
2. Mechanism-based inactivation of cytochrome P450 enzymes by natural products based on metabolic activation.
Zhang T; Rao J; Li W; Wang K; Qiu F
Drug Metab Rev; 2020 Nov; 52(4):501-530. PubMed ID: 33043714
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cytochrome P450 enzymes and biochemical aspects of mechanism-based inactivation (MBI).
Kamel A; Harriman S
Drug Discov Today Technol; 2013; 10(1):e177-89. PubMed ID: 24050247
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Fontana E; Dansette PM; Poli SM
Curr Drug Metab; 2005 Oct; 6(5):413-54. PubMed ID: 16248836
[TBL] [Abstract][Full Text] [Related]
5. Mechanism-Based Inactivation of Cytochrome P450 Enzymes: Computational Insights.
Mirzaei MS; Ivanov MV; Taherpour AA; Mirzaei S
Chem Res Toxicol; 2021 Apr; 34(4):959-987. PubMed ID: 33769041
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 inactivation by pharmaceuticals and phytochemicals: therapeutic relevance.
Johnson WW
Drug Metab Rev; 2008; 40(1):101-47. PubMed ID: 18259986
[TBL] [Abstract][Full Text] [Related]
7. The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition.
VandenBrink BM; Isoherranen N
Curr Opin Drug Discov Devel; 2010 Jan; 13(1):66-77. PubMed ID: 20047147
[TBL] [Abstract][Full Text] [Related]
8. Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications.
Hollenberg PF; Kent UM; Bumpus NN
Chem Res Toxicol; 2008 Jan; 21(1):189-205. PubMed ID: 18052110
[TBL] [Abstract][Full Text] [Related]
9. Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs.
Masubuchi Y; Horie T
Crit Rev Toxicol; 2007 Jun; 37(5):389-412. PubMed ID: 17612953
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4.
Zhou S; Chan E; Lim LY; Boelsterli UA; Li SC; Wang J; Zhang Q; Huang M; Xu A
Curr Drug Metab; 2004 Oct; 5(5):415-42. PubMed ID: 15544435
[TBL] [Abstract][Full Text] [Related]
11. Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation.
Venkatakrishnan K; Obach RS
Curr Drug Metab; 2007 Jun; 8(5):449-62. PubMed ID: 17584016
[TBL] [Abstract][Full Text] [Related]
12. Metabolic activation of drugs by cytochrome P450 enzymes: Biochemical insights into mechanism-based inactivation by fibroblast growth factor receptor inhibitors and chemical approaches to attenuate reactive metabolite formation.
Tang LWT; Chan ECY
Biochem Pharmacol; 2022 Dec; 206():115336. PubMed ID: 36332675
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 and Non-Cytochrome P450 Oxidative Metabolism: Contributions to the Pharmacokinetics, Safety, and Efficacy of Xenobiotics.
Foti RS; Dalvie DK
Drug Metab Dispos; 2016 Aug; 44(8):1229-45. PubMed ID: 27298339
[TBL] [Abstract][Full Text] [Related]
14. Xenobiotic Metabolising Enzymes: Impact on Pathologic Conditions, Drug Interactions and Drug Design.
Rekka EA; Kourounakis PN; Pantelidou M
Curr Top Med Chem; 2019; 19(4):276-291. PubMed ID: 30706817
[TBL] [Abstract][Full Text] [Related]
15. A Chemoproteomic Platform To Assess Bioactivation Potential of Drugs.
Sun R; Shi F; Liu K; Fu L; Tian C; Yang Y; Tallman KA; Porter NA; Yang J
Chem Res Toxicol; 2017 Oct; 30(10):1797-1803. PubMed ID: 28960974
[TBL] [Abstract][Full Text] [Related]
16. Inhibition and induction of cytochrome P450 and the clinical implications.
Lin JH; Lu AY
Clin Pharmacokinet; 1998 Nov; 35(5):361-90. PubMed ID: 9839089
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450 Structure, Function and Clinical Significance: A Review.
Manikandan P; Nagini S
Curr Drug Targets; 2018; 19(1):38-54. PubMed ID: 28124606
[TBL] [Abstract][Full Text] [Related]
18. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486).
He K; Woolf TF; Hollenberg PF
J Pharmacol Exp Ther; 1999 Feb; 288(2):791-7. PubMed ID: 9918590
[TBL] [Abstract][Full Text] [Related]
19. Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information.
Hisaka A; Ohno Y; Yamamoto T; Suzuki H
Pharmacol Ther; 2010 Feb; 125(2):230-48. PubMed ID: 19951720
[TBL] [Abstract][Full Text] [Related]
20. High-throughput cytochrome P450 loss and metabolic intermediate complex assays to aid in designing out of CYP3A inactivation.
Russell DA; Cerny MA
Methods Enzymol; 2023; 690():341-368. PubMed ID: 37858534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
